Treatment of Symptomatic Mild Colonic Crohn's Disease (Including Ileocolonic Involvement)
This first-line protocol targets patients with symptomatic mild colonic Crohn's disease, including those with ileocolonic involvement — but specifically excludes isolated small bowel disease, which follows a different management pathway.
Clinical scenario: Symptomatic mild colonic Crohn's disease (and/or ileocolonic), not isolated small bowel disease. The disease distribution is colonic or ileocolonic; small bowel-only involvement is outside the scope of this protocol.
Treatment Approach
An oral agent given in divided doses is used as first-line therapy, targeting improvement of symptoms in mild colonic Crohn's disease. The specific agent, complete dosing schedule, and full clinical decision framework are available in the structured protocol below.
References
DOI: 10.14309/ajg.0000000000003465
Sulfasalazine should only be considered for patients with symptomatic mild colonic CD.
Sulfasalazine, 3–6 g daily in divided doses, may be a modestly effective therapy for treatment of symptoms of patients with mild colonic CD and/or ileocolonic CD, but not isolated small bowel disease.
View source ↗